New hope for Hard-to-Treat lymphoma: experimental drug shows promise
NCT ID NCT05563844
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called purinostat mesylate in 74 adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer that has come back or not responded to treatment). The goal is to see if the drug can shrink tumors and control the disease, while also checking for side effects. Participants receive the drug by injection, and researchers measure how many people respond and for how long.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital of Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment